Every cancer patient enters remission after drug trial, study reveals

[Kamaji]

Every cancer patient enters remission after drug trial, study reveals

By Joe Tacopino   
June 6, 2022

A recent drug trial administered to a handful of cancer patients had the surprising result of eliminating the disease in every participant involved.

The study was conducted on 18 rectal cancer patients at Memorial Sloan Kettering Cancer Center in Manhattan and had a 100 percent success rate, according to a paper published Sunday in the New England Journal of Medicine.

“I believe this is the first time this has happened in the history of cancer,” Dr. Luis A. Diaz Jr, the author of the paper, told the New York Times.

The drug, dostarlimab, was administered to each patient every three weeks for six months.

*  *  *

Source:  https://nypost.com/2022/06/06/every-cancer-patient-enters-remission-after-drug-trial/

[PeteS in CA]

So, 8 or 9 infusions over that 6 months.

****mab means it's a monoclonal antibody.

18 is a very small sample, so a larger study is probably up next in any approval process. But I wonder how many people in the US at any given time have rectal cancer.

I wonder whether this mab might be usable with colon cancer.

[Smokin Joe]

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 –blocking monoclonal antibody

https://en.wikipedia.org/wiki/Dostarlimab

It is manufactured by Tesaro, which was bought by Glaxo Smith line in a 5.1 billion dollar buyout. https://www.fiercepharma.com/pharma/checkered-path-a-replay-how-tesaro-got-its-5-1-billion-glaxosmithkline-buyout